LU84356A1 - Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines - Google Patents

Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines Download PDF

Info

Publication number
LU84356A1
LU84356A1 LU84356A LU84356A LU84356A1 LU 84356 A1 LU84356 A1 LU 84356A1 LU 84356 A LU84356 A LU 84356A LU 84356 A LU84356 A LU 84356A LU 84356 A1 LU84356 A1 LU 84356A1
Authority
LU
Luxembourg
Prior art keywords
insulin
human
pro
proinsulin
weight ratio
Prior art date
Application number
LU84356A
Other languages
English (en)
French (fr)
Inventor
Bruce Hill Frank
Ronald Eugene Chance
John Allison Galloway
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of LU84356A1 publication Critical patent/LU84356A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LU84356A 1981-08-27 1982-08-26 Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines LU84356A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29671481A 1981-08-27 1981-08-27
US29671481 1981-08-27

Publications (1)

Publication Number Publication Date
LU84356A1 true LU84356A1 (fr) 1983-02-28

Family

ID=23143234

Family Applications (1)

Application Number Title Priority Date Filing Date
LU84356A LU84356A1 (fr) 1981-08-27 1982-08-26 Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines

Country Status (20)

Country Link
US (1) US4652547A (it)
JP (1) JPS5846025A (it)
AU (1) AU551733B2 (it)
BE (1) BE894188A (it)
CA (1) CA1176161A (it)
CH (1) CH650678A5 (it)
DE (1) DE3232033A1 (it)
DO (1) DOP1982004086A (it)
FR (1) FR2511867B1 (it)
GB (1) GB2105191B (it)
IL (1) IL66613A (it)
IT (1) IT1153181B (it)
LU (1) LU84356A1 (it)
MW (1) MW4082A1 (it)
NL (1) NL8203314A (it)
NZ (1) NZ201686A (it)
PH (1) PH18725A (it)
SE (1) SE8204874L (it)
ZA (1) ZA826158B (it)
ZW (1) ZW17582A1 (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
US4992417A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DK0467932T3 (da) * 1989-04-07 2001-02-12 Cancerforskningsfonden Af 1989 Plasminogen-aktivator-receptor af urokinasetypen
US5208217A (en) * 1989-04-20 1993-05-04 Mount Sinai School Of Medicine Of The City University Of New York Hepatospecific insulin analogues
WO1997011959A1 (en) * 1995-09-29 1997-04-03 Receptron, Inc. Biologically active mhc peptides having a repeated amino acid sequence motif
OA13136A (en) * 2001-05-21 2006-12-13 Nektar Therapeutics Pulmonary administration of chemically modified insulin.
MXPA04002404A (es) * 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
US7670984B2 (en) * 2006-01-06 2010-03-02 Headwaters Technology Innovation, Llc Hydrocarbon-soluble molybdenum catalyst precursors and methods for making same
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
US9939551B2 (en) 2012-09-24 2018-04-10 Schlumberger Technology Corporation Systems, devices and methods for borehole gravimetry
CA2899220A1 (en) * 2013-01-29 2014-08-07 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183849A (en) * 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana

Also Published As

Publication number Publication date
MW4082A1 (en) 1984-06-13
DE3232033A1 (de) 1983-03-10
IT1153181B (it) 1987-01-14
ZW17582A1 (en) 1982-11-17
DOP1982004086A (es) 1988-03-22
CH650678A5 (de) 1985-08-15
NZ201686A (en) 1985-08-30
CA1176161A (en) 1984-10-16
IL66613A (en) 1985-11-29
FR2511867A1 (fr) 1983-03-04
BE894188A (fr) 1983-02-24
PH18725A (en) 1985-09-11
ZA826158B (en) 1984-04-25
US4652547A (en) 1987-03-24
AU8759682A (en) 1983-03-03
GB2105191B (en) 1984-12-19
NL8203314A (nl) 1983-03-16
FR2511867B1 (fr) 1986-08-14
AU551733B2 (en) 1986-05-08
GB2105191A (en) 1983-03-23
IL66613A0 (en) 1982-12-31
SE8204874D0 (sv) 1982-08-25
JPS5846025A (ja) 1983-03-17
IT8223016A0 (it) 1982-08-27
SE8204874L (sv) 1983-02-28

Similar Documents

Publication Publication Date Title
BE1009408A5 (fr) Formulations d'analogues de l'insuline.
JP2828250B2 (ja) 真性糖尿病の治療
LU84356A1 (fr) Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines
RU2572214C2 (ru) Способ получения цинковых комплексов инсулина
EP1455814B1 (en) Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
US20030050228A1 (en) Methods of treating diabetes mellitus
Christophe et al. Effects of chronic treatment with carbutamide on distribution and biosynthesis of fatty acids and cholesterol in obese-hyperglycemic mice
JP2002534450A (ja) 新規なエキセンジンアゴニスト製剤とその投与方法
LU84359A1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
US4652548A (en) Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
CN111712236A (zh) 用于治疗糖尿病的包含基于脂质的纳米颗粒的组合物
Hayashi et al. Changes in blood pressure, urinary kallikrein, and urinary prostaglandin E 2 in rats with streptozotocin-induced diabetes
LU84358A1 (fr) Formulations pharmaceutiques de pro-insuline humaine
LU84357A1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine,un c-peptide humain et de la pro-insuline humaine
Shirohara et al. Effects of intravenous infusion of amino acids on cholecystokinin release and gallbladder contraction in humans
Patki et al. Progress made in non-invasive insulin delivery
US20120270778A1 (en) Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes
BE1013507A5 (fr) Formulations d'analogues de l'insuline.
FR2746313A1 (fr) Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques
EP4087596A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
WO2000001396A1 (fr) Composition pharmaceutique pour le traitement des dysfonctions sexuelles